Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Recombinant elastin based nanoparticles for targeted gene therapy.

Monfort DA, Koria P.

Gene Ther. 2017 Jul 5. doi: 10.1038/gt.2017.54. [Epub ahead of print]

PMID:
28681841
2.

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP.

Am J Gastroenterol. 2017 Jan;112(1):120-131. doi: 10.1038/ajg.2016.569. Epub 2016 Dec 13.

PMID:
27958281
3.

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.

Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez GE, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo Á, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, Van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo F, Gisbert JP; Spanish GETECCU group (ENEIDA project).

Inflamm Bowel Dis. 2016 Apr;22(4):894-901. doi: 10.1097/MIB.0000000000000757.

PMID:
26933750
4.

Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study.

Nunes T, Etchevers MJ, García-Sánchez V, Ginard D, Martí E, Barreiro-de Acosta M, Gomollón F, Arroyo M, Bastida G, Gonzalez B, Monfort D, García-Planella E, Figueroa C, Panés J, Sans M.

Am J Gastroenterol. 2016 Mar;111(3):411-9. doi: 10.1038/ajg.2015.401. Epub 2016 Feb 9.

PMID:
26856753
5.

Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.

Chaparro M, Barreiro-de Acosta M, García-Planella E, Domènech E, Bermejo F, Calvet X, Martín Arranz MD, Monfort D, Gisbert JP.

Gastroenterol Hepatol. 2016 Apr;39(4):255-60. doi: 10.1016/j.gastrohep.2015.06.007. Epub 2015 Nov 24.

PMID:
26620278
6.

Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).

Loras C, Gisbert JP, Saro MC, Piqueras M, Sánchez-Montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-Bañares F, Esteve M; REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa).

J Crohns Colitis. 2014 Nov;8(11):1529-38. doi: 10.1016/j.crohns.2014.06.009. Epub 2014 Jul 19.

PMID:
25052345
7.

[Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions].

Piqueras M, Monfort D, Pol MA, Galter S, Modolell I, Ortiz J, Boadas J.

Gastroenterol Hepatol. 2013 Jun-Jul;36(6):396-9. doi: 10.1016/j.gastrohep.2013.02.007. Epub 2013 Apr 12. Spanish. No abstract available.

PMID:
23587662
8.

Development and testing of a new instrument to measure patient satisfaction with health care in inflammatory bowel disease: the CACHE questionnaire.

Casellas F, Ginard D, Vera I, Torrejón A; GETECCU.

Inflamm Bowel Dis. 2013 Mar;19(3):559-68. doi: 10.1097/MIB.0b013e31827febd1.

PMID:
23429448
9.

High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study.

Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Martí E, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU.

J Crohns Colitis. 2013 Apr;7(3):202-7. doi: 10.1016/j.crohns.2012.04.011. Epub 2012 May 23.

PMID:
22626507
10.

Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients.

Azuara D, Rodriguez-Moranta F, de Oca J, Sanjuan X, Guardiola J, Lobaton T, Wang A, Boadas J, Piqueras M, Monfort D, Galter S, Esteller M, Moreno V, Capellá G.

Inflamm Bowel Dis. 2013 Jan;19(1):165-73. doi: 10.1002/ibd.22994.

PMID:
22532293
11.

Does smoking influence Crohn's disease in the biologic era? The TABACROHN study.

Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU, Spanish Working Group in Crohn's Disease and Ulcerative Colitis.

Inflamm Bowel Dis. 2013 Jan;19(1):23-9. doi: 10.1002/ibd.22959.

PMID:
22467185
12.

Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.

Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, Iglesias E, Gomez-Senent S, Torres Y, Ponferrada A, Arevalo JA, Hernandez V, Calvet X, Ginard D, Monfort D, Chaparro M, Manceñido N, Domínguez-Antonaya M, Villalón C, Perez-Calle JL, Muñoz C, Nuñez H, Carpio D, Aramendiz R, Bujanda L, Estrada-Oncins S, Hermida C, Barrio J, Casis MB, Dueñas-Sadornil MC, Fernández L, Calvo-Cenizo MM, Botella B, de Francisco R, Ayala E, Sans M; RECLICU Study Group of GETECCU.

J Crohns Colitis. 2010 Dec;4(6):629-36. doi: 10.1016/j.crohns.2010.07.003.

PMID:
21122572
13.

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, Pascual S, Monfort D, Montoliu S, Vila C, Escudero A, Torras X, Cirera I, Llanos L, Guarner-Argente C, Palazón JM, Carnicer F, Bellot P, Guarner C, Planas R, Solá R, Serra MA, Muñoz C, Pérez-Mateo M, Such J.

Hepatology. 2008 Dec;48(6):1924-31. doi: 10.1002/hep.22564.

PMID:
19003911
14.

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F; International Study Group on rFVIIa in UGI Hemorrhage.

Hepatology. 2008 May;47(5):1604-14. doi: 10.1002/hep.22216.

PMID:
18393319
15.

Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.

García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ; Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham).

Aliment Pharmacol Ther. 2008 May;27(9):780-9. doi: 10.1111/j.1365-2036.2008.03655.x. Epub 2008 Feb 18.

16.

Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype.

Cantó E, Ricart E, Busquets D, Monfort D, García-Planella E, González D, Balanzó J, Rodriguez-Sanchez JL, Vidal S.

World J Gastroenterol. 2007 Nov 7;13(41):5446-53.

17.

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V.

Gastroenterology. 2007 Sep;133(3):818-24. Epub 2007 Jul 3.

PMID:
17854593
18.

Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study.

Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panes J.

World J Gastroenterol. 2007 Apr 21;13(15):2193-7.

19.

Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.

Salar A, Bessa X, Muñiz E, Monfort D, Besses C, Andreu M.

Gut. 2007 Aug;56(8):1169-70. Epub 2007 Mar 7. No abstract available.

20.

A case of vulvar pyoderma gangrenosum associated with collagenous colitis.

Roé E, Dalmau J, García-Navarro X, Corella F, Monfort D, Busquets D, Ribé A, Delgado E, Alomar A.

Dermatology. 2006;213(3):234-5.

PMID:
17033174

Supplemental Content

Loading ...
Support Center